Counter({'OF': 3786, 'IN': 2944, 'FOR': 2463, '2016': 2100, 'PHASE': 2015, 'THE': 1819, '2015': 1742, 'ANNOUNCES': 1735, 'CLINICAL': 1470, 'AND': 1323, 'TO': 1269, 'WITH': 1218, 'DATA': 1160, 'TRIAL': 1154, 'AT': 1080, '2014': 1022, 'CANCER': 792, '12': 791, 'XOMA': 772, 'STUDY': 727, '09': 723, '3': 709, 'RESULTS': 708, 'FROM': 683, '2': 676, 'PATIENTS': 676, 'ON': 671, '06': 670, 'TREATMENT': 658, '10': 637, 'MEETING': 636, 'S': 634, '05': 624, '01': 620, '03': 616, '11': 603, 'PHARMACEUTICALS': 602, '07': 534, 'ANNUAL': 530, 'POSITIVE': 525, 'SELINEXOR': 512, 'KARYOPHARM': 512, '04': 497, '08': 488, 'FDA': 423, '02': 403, 'PRESENT': 396, '2017': 386, 'DRUG': 346, 'NEW': 346, '2013': 346, 'FIRST': 327, 'A': 324, 'ALDOXORUBICIN': 324, 'CYTRX': 315, 'PRESENTS': 312, 'INITIATES': 297, 'THERAPEUTICS': 296, 'REPORTS': 288, '1': 286, 'DISEASE': 285, 'SOCIETY': 272, 'EUROPEAN': 266, 'AMERICAN': 265, 'COMBINATION': 253, 'ENROLLMENT': 248, 'ONCOLOGY': 242, 'KPT': 240, '330': 240, 'UPDATE': 235, '30': 234, 'PROGRAM': 232, 'PATIENT': 223, 'RECEIVES': 217, 'CELL': 211, 'ORAL': 211, '16': 208, '19': 205, '28': 200, 'LINE': 196, 'MULTIPLE': 192, 'DESIGNATION': 189, 'R': 188, 'DEVELOPMENT': 183, 'BIOPHARMA': 179, '27': 177, '21': 177, 'PIVOTAL': 176, '29': 174, 'CONFERENCE': 174, '22': 173, 'SECOND': 171, 'APPLICATION': 171, 'INTERIM': 170, '14': 162, '2B': 158, 'PROVIDES': 158, 'PRESENTATION': 157, 'U': 157, 'REDHILL': 153, 'ITS': 152, 'ADVANCED': 150, '13': 150, '18': 149, 'ONCOGENEX': 144, 'STOCK': 144, 'METASTATIC': 143, '24': 142, 'QUARTER': 141, '25': 141, '23': 141, 'CONGRESS': 141, 'ANNOUNCE': 140, 'PRESENTED': 139, 'AS': 139, 'FINANCIAL': 137, 'RHB': 135, '1B': 133, 'LUNG': 131, '15': 130, 'GLOBAL': 130, 'ASSOCIATION': 129, '20': 128, 'SARCOMA': 128, 'BREAST': 128, 'ASCO': 127, '104': 126, 'ORPHAN': 125, 'TISSUE': 124, 'HEMATOLOGY': 123, 'TRIALS': 122, 'III': 120, 'COMPLETES': 120, 'SOFT': 119, 'PUBLICATION': 119, 'PRESENTATIONS': 117, 'PUMA': 117, 'BIOTECHNOLOGY': 117, 'NERATINIB': 117, '17': 116, 'SMALL': 115, 'COMPLETION': 114, 'SYNDROME': 112, 'REPROS': 111, '2012': 111, 'PRECLINICAL': 110, 'BY': 110, 'PROELLEX': 108, 'CHRONIC': 108, 'TOP': 108, 'ONGOING': 107, 'NON': 106, 'SYNERGY': 106, 'HOST': 101, 'GRANTED': 100, 'ENOBOSARM': 100, 'JOURNAL': 100, 'TUMOR': 99, 'PAIN': 99, 'ADDITIONAL': 99, 'IS': 99, 'RESEARCH': 99, 'PATENT': 98, 'SURVIVAL': 98, 'ASH': 98, 'INVESTIGATIONAL': 98, 'WEEK': 97, 'TWO': 97, 'TODAY': 96, 'GTX': 96, 'SEVERE': 95, 'EVALUATING': 94, 'INITIATION': 93, 'CRLX101': 92, 'PANCREATIC': 92, 'CANDIDATE': 91, 'INTERNATIONAL': 91, 'STUDIES': 90, '26': 90, 'SYMPOSIUM': 88, 'PLECANATIDE': 88, 'CONSTIPATION': 87, 'CEMPRA': 87, 'ACELRX': 86, 'ANALYSIS': 86, 'CROHN': 84, 'HEMATOLOGIC': 84, 'AGREEMENT': 83, 'II': 83, 'THERAPY': 82, 'CALL': 81, 'SOLITHROMYCIN': 81, 'CUSTIRSEN': 81, 'BIOLINERX': 80, 'LEAD': 80, 'MYELOMA': 80, '8040': 80, 'DOSE': 80, 'BL': 80, 'CERULEAN': 80, 'PUBLISHED': 79, 'TOPLINE': 78, 'SOLID': 78, 'RELAPSED': 76, 'REXAHN': 76, 'STAGE': 75, 'ACUTE': 74, 'YEAR': 73, 'FOSTAMATINIB': 72, 'REGISTRATION': 72, 'ULTRAGENYX': 72, 'RESISTANT': 72, 'EPIDIOLEX': 72, 'UPDATED': 71, 'TRADING': 70, 'POTENTIAL': 69, 'TM': 69, 'AACR': 69, 'HIGH': 68, 'B': 68, 'MEDICINES': 68, 'RX': 68, 'UPCOMING': 68, 'EFFICACY': 68, 'OPTIONS': 68, 'ANTI': 67, 'AN': 67, 'TRACK': 67, 'DISCUSS': 66, 'APATORSEN': 66, 'OVARIAN': 66, 'FULL': 65, 'GLIOBLASTOMA': 65, 'TUMORS': 64, '31': 64, 'BIOLOGICS': 64, 'FAST': 64, 'GW': 63, 'RIGEL': 63, 'PUBLISHES': 63, 'PB272': 63, 'MARKETING': 62, 'POST': 62, 'EARLY': 61, 'I': 61, 'EXTENDED': 61, 'UTERINE': 60, 'SCLEROSIS': 60, 'ACTIVITY': 60, 'FOURTH': 59, 'SHOWING': 59, 'BE': 59, 'PRIMARY': 58, 'COMPANY': 58, 'NOVEL': 58, '3117': 58, 'WEBCAST': 58, 'THIRD': 58, 'VOLUME': 57, 'INHIBITOR': 57, 'APPROVAL': 57, 'REFRACTORY': 56, 'PROSTATE': 56, '2A': 56, 'ACCEPTANCE': 56, 'HOLD': 56, 'ADULTS': 56, 'SUBMITS': 55, 'AUTHORIZATION': 55, 'SAFETY': 55, 'REVIEW': 55, 'MALIGNANCIES': 55, 'SCIENTIFIC': 55, 'CARCINOMA': 54, 'BIOSCIENCES': 54, 'CANCERS': 54, 'NDA': 54, 'ALKS': 53, 'THAT': 53, 'IDIOPATHIC': 53, 'SARCOMAS': 52, 'NKTR': 52, 'CORPORATION': 52, 'ACHIEVEMENTS': 52, 'MILLION': 52, '2011': 52, 'REMOXY': 52, 'HER2': 51, 'CONCEPT': 51, 'PROOF': 51, 'PHARMA': 51, 'PLUS': 51, 'ZALVISO': 50, 'ANTHERA': 50, 'BLADDER': 50, 'PARKINSON': 50, 'RENAL': 49, 'DYSTROPHY': 49, 'MUSCULAR': 49, 'ESMO': 49, 'FIBROIDS': 48, 'RSV': 48, 'KRN23': 48, 'COLLABORATION': 48, 'NOVAVAX': 48, 'IIA': 47, 'ASSOCIATED': 47, 'RELATED': 47, 'VACCINE': 47, 'LONG': 47, 'FOLLOWING': 47, 'MUSCLE': 47, 'DOSED': 47, 'PREVENTION': 47, 'DUCHENNE': 46, 'PARTIAL': 46, 'AERIE': 46, 'PEDIATRIC': 46, 'MODERATE': 46, 'HEALTHCARE': 45, 'DEMONSTRATING': 45, 'HIGHLIGHTS': 45, 'OPEN': 45, 'WOMEN': 45, 'ITP': 45, 'ADJUVANT': 45, 'INC': 44, 'F': 44, 'CAT': 44, 'ACTION': 44, 'PRODUCT': 44, 'ALKERMES': 44, 'ARX': 44, '358': 44, 'C': 43, 'APRICUS': 43, 'VITAROS': 43, 'MIGALASTAT': 42, 'ABSTRACTS': 42, 'AGENT': 42, 'DOSING': 42, 'TYPE': 42, 'SAGE': 42, 'PRE': 41, 'LYMPHOMA': 40, 'WORLD': 40, 'FIBROSIS': 40, 'COMMITTEE': 40, 'ENDPOINT': 40, '214': 40, 'POSTER': 40, 'HEMOPHILIA': 40, 'GRANTS': 40, 'LOW': 39, 'SUPPORTING': 39, 'CHEMOCENTRYX': 38, 'HEAT': 38, 'HS': 38, 'MEDICAL': 38, '0': 38, 'COVERING': 38, 'ALERT': 38, 'PORTOLA': 38, 'HUMAN': 38, 'EPILEPSY': 38, 'RESPONSE': 38, 'BLISIBIMOD': 38, 'X': 37, 'LIVER': 37, 'RECEPTOR': 37, 'DISORDER': 37, 'ALLOWANCE': 37, 'COMMERCIALIZATION': 37, 'ORALLY': 37, 'MEETS': 37, 'LICENSE': 37, 'COMMON': 36, 'ACCELERON': 36, '060': 36, 'UNIQURE': 36, 'IFOSFAMIDE': 36, 'EUROPE': 36, 'CONFERENCES': 36, 'BLUEBIRD': 36, 'CYSTIC': 36, 'PROTEON': 36, 'PLANNED': 36, 'GEMCITABINE': 36, 'WASTING': 36, 'VONAPANITASE': 36, 'BIO': 36, 'AMT': 36, 'NEKTAR': 36, 'FABRY': 36, 'MESNA': 36, 'SOLUTION': 35, 'DURECT': 35, 'SUPINOXIN': 34, 'NOTICE': 34, 'MEDICINE': 34, 'HEALTH': 34, 'UNITED': 34, 'TREATED': 34, 'TREATING': 34, 'LUSPATERCEPT': 34, 'OVERALL': 34, 'IIB': 33, 'COMMISSION': 33, 'AGENCY': 33, 'LENNOX': 33, 'GASTAUT': 33, 'TREAT': 33, 'CHILDREN': 33, 'LABEL': 33, 'KEY': 33, 'SECONDARY': 33, 'LEUKEMIA': 32, 'THALASSEMIA': 32, 'IMMUNOTHERAPY': 32, 'REGULATORY': 32, 'EIGER': 32, 'STORM': 32, 'DIRECTED': 32, 'COMPLETE': 32, 'NSCLC': 32, 'INVESTOR': 31, 'PNEUMONIA': 31, 'TG': 31, 'TARGET': 31, 'ENCLOMIPHENE': 30, 'JAPAN': 30, 'AMICUS': 30, 'INDUCED': 30, 'DYSFUNCTION': 30, 'OLDER': 30, 'CARE': 30, 'BACTERIAL': 30, 'ENDOMETRIOSIS': 30, '6': 30, 'TERM': 30, 'MEN': 30, 'LINKED': 30, 'CBD': 30, 'ADMINISTERED': 30, 'BOREALIS': 30, 'ACHIEVES': 30, 'INITIAL': 30, 'HYPOPHOSPHATEMIA': 30, 'CANNABIDIOL': 30, 'OPTION': 30, 'WEAK': 30, 'SUPPORT': 29, '4': 29, 'ER': 29, 'DEMONSTRATE': 29, 'AVASTIN': 29, 'FREE': 29, 'MAY': 28, '101': 28, 'CHEMOTHERAPY': 28, 'HEAD': 28, 'OFFERING': 28, 'BETA': 28, 'OCULAR': 28, '7': 28, 'SYNTHETIC': 28, 'CTOS': 28, 'PROGRAMS': 28, 'ADVISORY': 28, 'GEVOKIZUMAB': 28, 'CCX168': 28, 'PROTOCOL': 27, 'RIZAPORT': 27, 'LETTER': 27, 'MALIGNANT': 27, 'SUBMISSION': 27, 'DESIGNATIONS': 27, 'UNION': 27, 'COMMUNITY': 27, '21ST': 27, 'ACQUIRED': 27, 'OTHER': 27, 'EVALUATE': 27, 'STATUS': 27, 'STATES': 27, 'MANUFACTURING': 27, 'NOW': 26, 'ARTERY': 26, 'RUXOLITINIB': 26, 'BETRIXABAN': 26, 'ACID': 26, 'THERAPEUTIC': 26, 'INFECTION': 26, 'CONTINUES': 26, 'VASCEPA': 26, 'PROGRESS': 25, 'LANCET': 25, 'KITE': 25, 'IRRITABLE': 25, 'INTO': 25, 'IV': 25, 'USE': 25, 'STEM': 25, 'IBS': 25, 'IMMUNO': 25, 'MONOTHERAPY': 25, 'DISEASES': 25, 'PRELIMINARY': 25, 'UPDATES': 25, 'ACCEPTED': 25, 'NEGATIVE': 25, 'BOWEL': 25, 'OPHTHALMIC': 25, 'INFECTIONS': 25, '102': 24, 'INTERESTING': 24, 'SURGERY': 24, 'TRIPLE': 24, 'LONAFARNIB': 24, 'RXI': 24, 'UX007': 24, 'KEYTRUDA': 24, 'LENTIGLOBIN': 24, 'ENGLAND': 24, 'INTELGENX': 24, 'END': 24, 'BLEEDING': 24, 'AFTER': 24, 'ACLARIS': 24, 'TONIX': 24, 'C19': 24, 'PROGENICS': 24, 'FILING': 24, 'CASTRATE': 24, 'CLASS': 24, 'GROWTH': 24, 'TNX': 24, 'SAMCYPRONE': 24, 'BIOPHARMACEUTICALS': 24, 'RIGHTS': 24, 'KTE': 24, 'STRONG': 24, 'RHOPRESSATM': 24, 'AMARIN': 24, 'DEAD': 24, 'INNOCOLL': 24, 'ADAMAS': 23, 'DIABETES': 23, 'ADS': 23, 'BREAKTHROUGH': 23, 'AGAINST': 23, 'TECHNOLOGIES': 23, 'ADULT': 23, 'STRATEGIC': 23, 'RECENT': 23, 'IB': 23, '5': 23, 'MUTANT': 23, '5102': 23, 'SAPACITABINE': 23, '003': 23, 'PLANS': 23, 'OR': 23, 'BOUNCE': 23, 'NEUROLOGY': 23, 'LEVODOPA': 23, 'SYMPTOMATIC': 23, 'TRC105': 22, 'TRACON': 22, '004': 22, 'ISSUANCE': 22, '547': 22, '410': 22, 'NETARSUDIL': 22, 'JAKAFI': 22, 'KNEE': 22, 'SYN': 22, 'VASCULITIS': 22, 'ACADEMY': 22, 'COMPLETED': 22, 'SL': 22, 'SC': 22, 'LUBIPROSTONE': 22, 'ADMINISTRATION': 22, 'CORMEDIX': 22, 'PALATIN': 22, 'COMPLEMENT': 22, 'BREMELANOTIDE': 22, 'NEUTROLIN': 22, 'TEVA': 22, 'DAY': 22, 'ANCA': 22, '1004': 21, 'SAN': 21, 'ACCESS': 21, 'DIABETIC': 21, 'KIDNEY': 21, 'TELOTRISTAT': 21, 'HEPATITIS': 21, 'BRAIN': 21, 'COMPOSITION': 21, 'NATIONAL': 21, 'DEPENDENT': 21, 'OUTLINES': 21, 'TIVANTINIB': 21, 'TRANSLARNA': 21, 'DEMONSTRATES': 21, 'CHECKPOINT': 21, 'SIGNS': 21, 'THREE': 21, 'ERECTILE': 21, 'EXCLUSIVE': 21, 'MIGRAINE': 21, 'RECURRENT': 21, 'POWER': 20, 'ENDO': 20, 'ZENTARIS': 20, 'PERILOUS': 20, 'PROGRESSION': 20, 'AETERNA': 20, 'HYPOGLYCEMIA': 20, 'AR': 20, 'CATABASIS': 20, 'MILESTONE': 20, 'REVERSAL': 20, 'BOTH': 20, 'SUCCESSFUL': 20, 'HAS': 20, 'GRANT': 20, 'BENEFIT': 20, 'CONGENITAL': 20, 'OSTEOARTHRITIS': 20, 'ENZALUTAMIDE': 20, 'PERIPHERAL': 20, 'GANAXOLONE': 20, 'AUGUST': 20, 'INFINITY': 20, 'AML': 20, 'ANTICANCER': 20, 'NHL': 20, 'HGB': 20, 'DUVELISIB': 20, 'MATTER': 20, 'EXTENSION': 20, 'SELECTED': 20, 'DEFICIENCY': 20, 'ALFA': 20, 'SEPTEMBER': 20, 'SOLLPURA': 20, 'HYPERINSULINISM': 20, 'APPLICATIONS': 19, 'SINGLE': 19, 'AGENTS': 19, 'MONTH': 19, 'PRICING': 19, 'UNIVERSITY': 19, 'FIELDS': 19, 'ARTHRITIS': 19, 'ABRAXANE': 19, 'ANTONIO': 19, 'FINAL': 19, 'GALENA': 19, 'ALCOBRA': 19, 'NOVEMBER': 19, 'RECOMMENDATION': 19, 'FURTHER': 19, 'MDX': 19, 'DOSES': 19, 'MYELODYSPLASTIC': 19, 'NEUVAX': 19, 'SYNDROMES': 19, 'FORWARD': 19, 'HYPOGONADISM': 19, 'REQUIREMENTS': 19, 'T': 19, 'LATE': 19, 'PLAN': 19, 'MUTATION': 18, 'PULMAQUIN': 18, 'RICHTER': 18, 'CARBAVANCE': 18, 'FIT': 18, 'OUTCOMES': 18, 'MDCO': 18, 'LICENSING': 18, 'FOOD': 18, 'MULTIFORME': 18, '216': 18, 'RHEUMATOID': 18, 'OGX': 18, 'V': 18, 'ACHILLION': 18, 'ARQULE': 18, 'MENSTRUAL': 18, 'GOING': 18, 'RAINIER': 18, 'LAUNCHES': 18, 'HIV': 18, 'GENITOURINARY': 18, 'ETIPRATE': 18, 'LEXICON': 18, 'DRAVET': 18, 'EVENTS': 18, 'KAPOSI': 18, 'NATURE': 17, 'PLATFORM': 17, 'LINACLOTIDE': 17, 'MODELS': 17, 'CYCLACEL': 17, 'ONCOMED': 17, 'PEGPH20': 17, 'TAREXTUMAB': 17, 'FOCUS': 17, 'KRAS': 17, 'JUNE': 17, 'CMX157': 17, 'ACHAOGEN': 17, 'NELIPEPIMUT': 17, 'INVESTIGATE': 17, 'PART': 17, 'SEXUAL': 17, 'MARKET': 17, 'CLOSING': 17, 'ASIAN': 17, 'DYSKINESIA': 17, 'SHORT': 17, 'GLAUCOMA': 17, 'INTEREST': 17, 'DIFFICILE': 17, 'RELEASE': 17, '20TH': 17, 'ANTIBODY': 17, 'FEATURED': 17, 'SECURITIES': 17, 'COHORT': 17, '2010': 17, 'ARADIGM': 17, 'PLAZOMICIN': 17, 'PATH': 17, 'UP': 17, 'STOP': 17, 'PRETREATED': 16, 'ZOPTREX': 16, 'TRANSFORMATION': 16, 'WARTS': 16, 'INITIATE': 16, '174': 16, 'HEAVILY': 16, 'TRADE': 16, 'STRESS': 16, 'CARDIOVASCULAR': 16, 'HALOZYME': 16, 'DIGESTIVE': 16, 'ACORDA': 16, 'CO': 16, 'SEBORRHEIC': 16, 'ASSESSMENT': 16, 'EFFECT': 16, 'FEMALE': 16, 'MECHANISM': 16, 'LENTIGLOBINTM': 16, 'CIC': 16, 'XARACOLL': 16, 'MARCH': 16, 'REVIEWS': 16, 'STOMP': 16, 'EMA': 16, 'NOVOCURE': 16, 'IDEAS': 16, '1101': 16, 'KERATOSIS': 16, 'SHAREHOLDER': 16, 'ACROSS': 16, 'IMPROVED': 16, 'MYELOID': 16, 'EYEGUARD': 16, 'CD122': 16, 'GYNECOLOGICAL': 16, 'BIASED': 16, 'SOPRA': 16, '302': 16, 'MOBILIZATION': 16, 'INCYTE': 16, 'PUT': 16, 'CYTOKINE': 16, 'LIPOSARCOMA': 16, 'TRANSFUSION': 16, 'CERDULATINIB': 16, '110': 16, 'LAUNCH': 16, 'US': 16, 'JANUARY': 16, 'IRONWOOD': 16, 'PAUSE': 16, 'LAST': 15, 'CONTINUATION': 15, 'HORMONE': 15, 'DUE': 15, 'PEMBROLIZUMAB': 15, 'SUCAMPO': 15, 'MAJOR': 15, 'PATHWAY': 15, 'SHOW': 15, 'FUNCTION': 15, 'PHARMACEUTICAL': 15, 'OTONOMY': 15, 'CONTRAVIR': 15, 'CUTANEOUS': 15, 'DEXTENZA': 15, 'INHALED': 15, 'MIGRAINES': 15, 'SQUAMOUS': 15, 'GALAFOLD': 15, 'OTIPRIO': 15, 'COMBINING': 15, '301': 15, 'EASL': 15, 'AFFINITY': 15, 'QIDP': 15, 'TECHNOLOGY': 15, 'THERAPEUTIX': 15, 'IVACAFTOR': 15, 'RELATIVE': 15, 'INCLUDING': 15, 'SUMMIT': 15, 'OPERATIVE': 15, 'MELANOMA': 15, 'COMPARED': 14, 'CELGENE': 14, 'GUIDANCE': 14, 'REDUCE': 14, 'AMITIZA': 14, 'LOCILEX': 14, 'COMMERCIAL': 14, 'GASTROINTESTINAL': 14, 'BEMPEDOIC': 14, 'CVT': 14, 'PTC': 14, 'TRADED': 14, 'TOPICAL': 14, 'ZOGENIX': 14, 'IND': 14, 'INSIDERS': 14, 'ABSTRACT': 14, 'INHIBITORS': 14, '1404': 14, 'RISK': 14, 'ZX008': 14, 'IDENTIFIED': 14, 'HIGHLIGHTED': 14, 'RANDOMIZATION': 14, 'ALD403': 14, 'SIGNIFICANT': 14, 'INSIDER': 14, 'EU': 14, 'ENCOURAGING': 14, 'TESARO': 14, 'MARINUS': 14, 'ENROLLS': 14, '17TH': 14, '18TH': 14, 'DIPEXIUM': 14, 'ENDPOINTS': 14, 'ASTRAZENECA': 14, 'MULTI': 14, '8217': 14, 'ROLAPITANT': 14, '8482': 14, 'ZILRETTA': 13, 'REACHES': 13, 'DISORDERS': 13, 'RNAI': 13, 'COMPOUND': 13, 'HEPATOCELLULAR': 13, 'ESPERION': 13, 'EXPANDS': 13, 'FILES': 13, 'ACCELERATOR': 13, 'YOUNG': 13, 'PATENTS': 13, 'SUBCUTANEOUS': 13, 'ENROLLED': 13, 'MOVEMENT': 13, 'ACCEPTS': 13, 'LUTATHERA': 13, 'INFECTIOUS': 13, 'FLEXION': 13, 'KITOV': 13, 'HEMOLYTIC': 13, 'ORKAMBI': 13, 'IMMUNE': 13, 'CELLS': 13, 'VALIDATION': 13, 'ESCALATION': 13, 'ALDER': 13, 'LOWER': 13, '002': 13, 'AASLD': 13, 'DIARRHEA': 13, 'COMMUNICATION': 13, 'PHYSICAL': 13, 'PROTECT': 13, 'KIT': 13, 'OCERA': 13, 'MODEL': 13, 'OCR': 13, 'PACLITAXEL': 12, 'FATTY': 12, 'SUCCESS': 12, 'LIPID': 12, 'PYODERMA': 12, 'OPERATIONAL': 12, 'CLEARANCE': 12, 'SPECIAL': 12, 'IMPROVEMENT': 12, 'GANGRENOSUM': 12, 'ATALUREN': 12, 'SIGN': 12, 'DMD': 12, 'OPINION': 12, 'ENSPIRIT': 12, 'FACTOR': 12, 'EXERCISE': 12, '5A': 12, 'IMMUNIZATION': 12, '427': 12, 'EPILEPTICUS': 12, 'CANADA': 12, 'ABALOPARATIDE': 12, 'ANALYSES': 12, 'MG': 12, 'MATERNAL': 12, 'LID': 12, 'PIPER': 12, 'ZUMA': 12, '928': 12, 'LOWR': 12, 'BOARD': 12, 'LUMACAFTOR': 12, '501': 12, 'RHOPRESSA': 12, 'VAGINAL': 12, 'SHOWS': 12, 'SICKLE': 12, 'CHAIN': 12, 'TRAUMATIC': 12, 'EXPOSITION': 12, 'ANDROGEN': 12, 'CAP': 12, 'ACQUIRES': 12, 'HDV': 12, '181': 12, 'OXIDATION': 12, 'PATHS': 12, 'WINDTREE': 12, 'GEN': 12, 'WEEKLY': 12, 'Q2': 12, 'GLUCOSE': 12, '9': 12, 'CHMP': 12, 'ACH': 12, 'SALE': 12, 'RECOMMENDS': 12, 'TRANSPORTER': 12, 'SURGICAL': 12, 'WELL': 12, 'SUPPLEMENTAL': 12, 'ALN': 12, '16TH': 12, 'ROCKET': 12, 'MEROPENEM': 12, 'COGENZIA': 12, 'DUR': 12, 'REQUESTS': 12, 'INDEPENDENT': 12, 'ALNYLAM': 12, 'AEROSURF': 12, 'DELTA': 12, 'STIMULATORY': 12, 'NEPHROPATHY': 12, 'GRAM': 12, 'FIBROID': 12, 'AGE': 11, 'AGS': 11, 'UNDER': 11, 'EVENT': 11, 'NOT': 11, 'COMMERCIALIZE': 11, 'F508DEL': 11, 'BASED': 11, 'CORPORATE': 11, 'PDUFA': 11, 'ACTIVE': 11, 'OBESE': 11, 'FILED': 11, 'IMAGING': 11, 'MEETINGS': 11, 'WILL': 11, 'MONITORING': 11, 'ADHD': 11, 'APRIL': 11, 'EYEGATE': 11, 'FOVISTA': 11, 'SCIENCES': 11, '437': 11, 'FOOT': 11, 'OPKO': 11, 'DSMB': 11, 'GASTROENTEROLOGY': 11, 'RADIUS': 11, 'OPHTHOTECH': 11, 'FUTILITY': 11, 'DATE': 11, 'MODIFYING': 11, 'NASH': 11, 'GENOCEA': 11, 'INSTITUTE': 11, 'REGARDING': 11, 'ROYALTY': 11, 'VERSUS': 11, 'LEVELS': 11, 'PROPHYLAXIS': 11, 'EGP': 11, 'RUCAPARIB': 11, 'REPORT': 11, '40': 11, 'TARGETED': 11, 'GASTRIC': 11, 'LIFE': 10, 'CTP': 10, 'PEER': 10, 'FORM': 10, 'AUSTRALIA': 10, 'JULY': 10, 'BIOMARIN': 10, 'AWARDED': 10, 'TOLERATED': 10, 'SKIN': 10, 'BIOTECH': 10, 'RECRUITMENT': 10, 'REVIEWED': 10, 'D': 10, 'EXPLORATORY': 10, 'BARICITINIB': 10, 'SUBMIT': 10, 'CERLIPONASE': 10, 'PIMAVANSERIN': 10, 'DEVELOP': 10, '98854': 10, 'GENE': 10, 'COPIES': 10, 'NEUROCRINE': 10, 'INOTEK': 10, 'PSORIASIS': 10, 'NBI': 10, 'ANEMIA': 10, 'SOUTH': 10, 'EXPANDED': 10, 'CCX872': 10, 'JANSSEN': 10, 'AVAILABLE': 10, 'ILL': 10, 'START': 10, 'ARIAD': 10, 'AL': 10, 'ISSUES': 10, 'KERYX': 10, 'SPONSORED': 10, 'DUAL': 10, 'EGALET': 10, 'HGH': 10, 'PRIORITY': 10, 'DERMATOLOGY': 10, 'ODALASVIR': 10, 'ANDEXANET': 10, 'NEXT': 10, 'OFF': 10, 'INHIBITION': 10, 'NIVOLUMAB': 10, 'APEX': 10, 'SUBSIDIARY': 10, 'ISOO': 10, 'MASCC': 10, 'FIBROMYALGIA': 10, 'TRABODENOSON': 10, 'AG': 10, 'AM': 10, 'SIMEPREVIR': 10, 'IGA': 10, 'MEDICINAL': 10, '335': 10, 'EXPECTED': 10, 'SITC': 10, 'GYNECOLOGIC': 10, '58TH': 10, 'MANAGED': 10, 'CEO': 10, 'DALANTERCEPT': 10, 'MEDICALLY': 10, 'ANTIBIOTIC': 10, 'DEPRESSION': 10, 'ICLUSIG': 10, 'SUPPORTIVE': 10, 'PLC': 10, 'REMOVAL': 10, 'AZEDRA': 10, 'AFFECTING': 10, 'INCLUDE': 10, 'BATTEN': 10, 'DURABLE': 10, 'BEGINS': 10, '166': 9, 'HEMATOLOGICAL': 9, 'MAA': 9, 'SPY': 9, '103': 9, 'MACULAR': 9, 'IMPLANT': 9, 'PEOPLE': 9, 'ANNOUNCED': 9, 'SUBLINGUAL': 9, 'PHARMACOLOGY': 9, 'OSTEOMALACIA': 9, 'NONSENSE': 9, 'ALL': 9, 'SCHIZOPHRENIA': 9, 'RESTRUCTURES': 9, 'EDASALONEXENT': 9, 'EXTENET': 9, 'SEIZURES': 9, '207': 9, 'QUALITY': 9, 'SUBSEQUENT': 9, 'TRIGGERING': 9, 'OSKIRA': 9, 'ESTABLISHES': 9, 'INTRAVENOUS': 9, 'MS': 9, 'AMERICA': 9, 'ND0612H': 9, 'INOPULSE': 9, 'AURYXIA': 9, 'WFH': 9, 'OUTSIDE': 9, 'TGR': 9, 'SHRINKAGE': 9, 'AUTOIMMUNE': 9, 'ENTER': 9, 'ACADIA': 9, 'DESIGN': 9, 'HERPES': 9, 'PARTNER': 9, 'STATISTICAL': 9, 'CTRC': 9, 'DESIGNS': 9, 'XLH': 9, '1202': 9, 'IMMEDIATE': 9, 'VABORBACTAM': 9, '191': 9, 'OSTEOPOROSIS': 9, 'SURGES': 9, 'CLOVIS': 9, 'POSTOPERATIVE': 9, 'LATANOPROST': 9, 'PREDNISONE': 9, 'ARDELYX': 9, 'WATCH': 9, 'AGES': 9, 'OVER': 9, 'ZEALAND': 9, 'STRATEGY': 9, 'GENITAL': 9, 'MN': 9, 'OCTOBER': 9, 'PHARMACOKINETIC': 9, 'FEDERATION': 9, 'ACG': 9, 'CARCINOID': 9, 'MET': 9, 'ADVANCES': 9, 'INVESTIGATION': 9, 'HYPOGONADAL': 9, 'NEURODERM': 9, 'LOPERAMIDE': 9, 'CAPSULES': 9, 'DURING': 9, 'PROMISING': 9, 'PROGRESSIVE': 9, 'KS': 9, 'BELLEROPHON': 9, '15TH': 9, 'PERMITTING': 9, 'FRAUD': 9, 'TENAPANOR': 9, 'BRONCHIECTASIS': 9, 'WRITTEN': 9, 'SPK': 8, 'SPA': 8, 'CIMZIA': 8, 'SUISSE': 8, 'LAWSUIT': 8, 'WHY': 8, '19TH': 8, 'DEVICE': 8, '1002': 8, 'CASTRATION': 8, 'GROSSMAN': 8, 'CONDITION': 8, 'BRONSTEIN': 8, 'OTITIS': 8, 'ASTELLAS': 8, 'REPORTED': 8, 'Q4': 8, 'EFFECTIVE': 8, 'XTANDI': 8, 'WET': 8, 'ABUSE': 8, '30PM': 8, 'LARGE': 8, 'CARDIOMYOPATHY': 8, 'ROSEN': 8, 'NORDISK': 8, 'OPEXA': 8, 'WEDBUSH': 8, 'YOSPRALA': 8, '50': 8, 'PAYMENT': 8, 'EXENDIN': 8, 'VERTEX': 8, 'PEGOL': 8, 'WHO': 8, 'INVASIVE': 8, 'SPARK': 8, 'LYNPARZA': 8, '4471': 8, 'CORBUS': 8, 'JEFFERIES': 8, 'SC1': 8, 'DECEMBER': 8, 'DAIICHI': 8, 'CAPRICOR': 8, 'ACTING': 8, 'ANDEXXA': 8, 'BAYER': 8, 'SANKYO': 8, 'NEUROPATHY': 8, 'PILOT': 8, 'VERSARTIS': 8, '57TH': 8, '69TH': 8, 'IMO': 8, 'GO1': 8, '205': 8, '206': 8, 'CORP': 8, 'IMMUNOGENICITY': 8, 'BICALUTAMIDE': 8, 'BYPASS': 8, 'COWEN': 8, 'KINGDOM': 8, 'ANALYST': 8, 'POSTPARTUM': 8, 'CREDIT': 8, 'SUBJECT': 8, 'COUNTRIES': 8, 'FIRM': 8, 'GEWIRTZ': 8, 'BARIATRIC': 8, 'PRIME': 8, 'CERTOLIZUMAB': 8, 'UROGUANYLIN': 8, 'PREVENT': 8, 'IBUDILAST': 8, 'LTD': 8, 'MATEON': 8, 'SPAIN': 8, 'HYPEROXALURIA': 8, 'ARALEZ': 8, 'RESUNAB': 8, 'HOLDINGS': 8, 'RANDOMIZED': 8, 'NOVO': 8, 'IDERA': 8, 'HODGKIN': 8, 'HEALTHY': 8, 'CLN2': 8, '8': 8, 'BRCA': 8, '317': 8, 'TCT': 8, 'GEL': 8, 'INFANTS': 8, 'CLONIDINE': 8, 'HAPTEN': 8, 'NORTHSTAR': 8, '005': 8, 'CONDUCT': 8, 'REGISTERED': 8, 'TAKEDA': 8, 'AMIKACIN': 8, 'PAINFUL': 8, 'MEDICINOVA': 8, 'ENDOCRINOLOGY': 8, 'ASCENDING': 8, 'JAFFRAY': 8, 'BIODELIVERY': 8, 'LAW': 8, '39': 8, 'VRS': 8, '5902': 8, 'MDS': 8, '2125': 8, 'FOUNDATION': 8, 'VIA': 8, 'URINARY': 8, 'PULMONARY': 8, 'REVANCE': 8, 'INHALATION': 8, 'DEADLINE': 8, 'TOVAXIN': 8, 'INVESTORS': 8, 'PATENCY': 8, 'MCG': 8, 'TRULANCE': 8, 'PACGROW': 8, 'WALKING': 8, 'PD': 8, 'CCR2': 8, 'DIRECTORS': 8, 'CHABLIS': 8, 'LUPUS': 8, 'POSTMENOPAUSAL': 8, '48': 8, 'CONTINUED': 8, 'CENTER': 8, 'LLP': 8, 'LLC': 8, 'REMINDS': 8, 'RPE65': 8, 'RT002': 8, 'LA': 7, 'SALES': 7, 'THERAPIES': 7, 'CONTINUE': 7, 'RECOMMENDATIONS': 7, 'PRESSURE': 7, 'MICROBE': 7, 'LEADERSHIP': 7, 'INDICATION': 7, 'ARGOS': 7, 'EANM': 7, 'CALADRIUS': 7, 'PROCESS': 7, 'CHEMICAL': 7, 'SOLIGENIX': 7, 'PIPELINE': 7, 'FUJIFILM': 7, 'BARDA': 7, 'SPARSENTAN': 7, 'JOLLA': 7, 'VALIDATES': 7, 'TREVENA': 7, 'EDUCATIONAL': 7, 'NUMBER': 7, 'TERRITORIES': 7, 'BIOMARKER': 7, 'ADVANCEMENT': 7, 'RETROPHIN': 7, 'LYMPHOCYTIC': 7, 'BIOTHERAPEUTICS': 7, 'CREAM': 7, 'MOLECULE': 7, 'SYSTEM': 7, 'PHEOCHROMOCYTOMA': 7, 'COLLEGE': 7, 'BREAKING': 7, 'CONTRACT': 7, 'GENERATION': 7, 'RESUBMISSION': 7, 'POSTERS': 7, 'CLBS03': 7, 'LJPC': 7, 'BLOOD': 7, 'ADOLESCENTS': 7, 'VITRO': 7, 'FOCAL': 7, 'DISTRIBUTION': 7, 'SUBMISSIONS': 7, 'KOREA': 7, 'VISIT': 7, 'INJECTABLE': 7, 'SGX301': 7, 'DEFINITIVE': 7, 'GOAL': 7, 'GAINS': 7, 'FRAGILE': 7, 'PARTNERSHIP': 7, 'SUPER': 7, 'DELIVERED': 7, 'SYSTEMIC': 7, 'HEPATIC': 7, 'MARK': 7, 'RELEASES': 7, 'PFIZER': 7, 'EFFECTS': 7, 'FOUR': 7, 'UVEITIS': 7, 'MANAGEMENT': 7, 'SUSTAINED': 7, 'ASM': 7, 'DEGENERATION': 7, 'ENCEPHALOPATHY': 7, 'LICENSES': 7, 'PROPRIETARY': 7, 'SESSION': 7, 'OLICERIDINE': 7, 'INCREASING': 7, 'TRANSFER': 7, 'PROCEED': 7, 'MAP': 6, 'GRAFT': 6, 'INNOVATIVE': 6, 'CABAZITAXEL': 6, 'TIPIFARNIB': 6, 'INTRODUCES': 6, 'LEVOSIMENDAN': 6, 'EZUTROMID': 6, 'PTSD': 6, 'CLOTS': 6, 'AGREEMENTS': 6, 'MYELOFIBROSIS': 6, 'GI': 6, '3831': 6, 'JUSTE': 6, 'COLORECTAL': 6, 'INTRAOCULAR': 6, 'QR': 6, 'NICE': 6, 'COMBINED': 6, 'INFANTILE': 6, 'KURA': 6, 'UROLOGICAL': 6, 'APPROVES': 6, 'SARAH': 6, 'SOLITHERA': 6, 'CORONARY': 6, 'SPECIFIC': 6, 'PROVIDE': 6, 'SUGGESTS': 6, 'UNANIMOUS': 6, 'AGILE': 6, 'ORBIT': 6, 'GENOTYPE': 6, '1011': 6, 'EDT': 6, 'SEIZURE': 6, 'LILLY': 6, 'ALLOWED': 6, 'MOVEDMDSM': 6, 'WALES': 6, 'PHARMATRONIC': 6, 'CERVICAL': 6, 'NCI': 6, 'CARBOPLATIN': 6, 'LASMIDITAN': 6, 'RARE': 6, 'MINNESOTA': 6, 'REACHED': 6, 'TWIRLA': 6, 'CHINA': 6, 'COPD': 6, 'MYCOBACTERIA': 6, 'ATYR': 6, 'INDICATIONS': 6, 'METADOXINE': 6, 'CBDV': 6, 'RESOLARIS': 6, 'RECLASSIFIES': 6, 'SHEET': 6, 'NONTUBERCULOUS': 6, 'MOVEDMD': 6, 'MICROBIOME': 6, 'ETHYL': 6, 'ROCLATANTM': 6, '31ST': 6, 'ISRAELI': 6, 'ADALIMUMAB': 6, 'COURSES': 6, 'TESTOSTERONE': 6, 'SUPPORTS': 6, 'ANNOUNCEMENT': 6, 'CEDAR': 6, 'ASIA': 6, 'PEARL': 6, 'RUNNING': 6, 'HEADACHE': 6, 'TENAX': 6, 'L': 6, 'DALFAMPRIDINE': 6, 'GOVERNMENT': 6, 'MATRIX': 6, 'EX': 6, 'PEMETREXED': 6, 'ASBMR': 6, 'IMPACT': 6, 'SPECTRUM': 6, 'TANGO': 6, 'PH1': 6, 'NEUROENDOCRINE': 6, 'OCCURRING': 6, 'AGGRESSIVE': 6, 'BEING': 6, 'TCR': 6, 'HEMODIALYSIS': 6, 'VAGINALLY': 6, 'OFFICE': 6, 'FINDINGS': 6, 'CLEAR': 6, 'THORACIC': 6, 'FACETS': 6, 'IMPROVING': 6, 'HAVE': 6, 'MILESTONES': 6, 'MYC': 6, 'FUTURE': 6, 'ERYTHEMATOSUS': 6, 'C5A': 6, 'HIGHLY': 6, 'PROQR': 6, 'TV': 6, '010': 6, '011': 6, 'COLUCID': 6, 'FIVE': 6, 'HEART': 6, 'CANNON': 6, 'INITIATED': 6, 'ADURO': 6, 'HCV': 6, 'TOYAMA': 6, 'OPIOID': 6, 'ROBUST': 6, 'GRUPO': 6, 'PRODUCES': 6, 'DURATION': 6, 'FIFTH': 6, 'POOR': 6, 'NORTHWESTERN': 6, 'INTRODUCTION': 6, 'ENTERS': 6, 'ENDOCRINE': 6, 'SUCCESSFULLY': 6, 'SUPERIOR': 6, 'BENEFITS': 6, 'FERRING': 6, 'SPRUCE': 6, 'SPASMS': 6, 'BUPIVACAINE': 6, 'REDUCTION': 6, 'REDUCED': 6, 'INTRA': 6, 'ADVANCE': 6, 'COLLAGEN': 6, 'SUFENTANIL': 6, 'PHYSICIAN': 6, 'MACI': 6, 'REMAINING': 5, 'ALLERGAN': 5, 'ELIGIBILITY': 5, '100': 5, 'ITALY': 5, 'PANEL': 5, 'PARTNERS': 5, 'EPISODES': 5, 'DECISION': 5, 'COMPELLING': 5, 'APL': 5, 'ADDRESS': 5, 'AFM13': 5, 'DEVELOPING': 5, 'OPENS': 5, '001': 5, 'PERCENT': 5, 'ROYALTIES': 5, 'UNDERLYING': 5, 'CKD': 5, 'LIVE': 5, 'DCR': 5, 'BREAKER': 5, 'CLOSED': 5, 'IMMUNITY': 5, 'TYPES': 5, 'UBLITUXIMAB': 5, 'RECEIPT': 5, 'MEDIATED': 5, 'GLEMBATUMUMAB': 5, 'DRY': 5, 'PLACEBO': 5, 'REGIMEN': 5, 'IBRUTINIB': 5, '5461': 5, 'SYNERGISTIC': 5, 'ONSET': 5, 'FOLLOW': 5, 'COMMENCEMENT': 5, 'SESSIONS': 5, 'COMMENCES': 5, 'EMERGENCY': 5, 'BIOEQUIVALENCE': 5, 'PREPARATION': 5, 'HYPERTENSION': 5, '3019': 5, 'FG': 5, 'PDL': 5, 'VERICEL': 5, '54TH': 5, 'ATEZOLIZUMAB': 5, 'PORTFOLIO': 5, 'FOCUSED': 5, 'CUTI': 5, 'NUPLAZID': 5, 'SHOWN': 5, 'SAFE': 5, 'ACCELERATED': 5, 'UNDERGOING': 5, 'PDGF': 5, 'VOTES': 5, 'IMPAIRMENT': 5, 'WHEN': 5, 'PRICE': 5, 'CHILD': 5, 'FINALIZES': 5, 'FEEDBACK': 5, 'ALLERGIC': 5, 'MARKED': 5, 'DEPRESSIVE': 5, 'CERECOR': 5, 'DEFECTS': 5, 'VIREAD': 5, 'APPROXIMATELY': 5, 'VTV': 5, '8700': 5, '13TH': 5, 'CITRATE': 5, 'SAYS': 5, 'FERRIC': 5, 'LOCK': 5, 'CIPROFLOXACIN': 5, 'PSYCHOSIS': 5, 'NONCLINICAL': 5, 'FIBROGEN': 5, 'EXPANSION': 5, 'EASE': 5, 'AFFIMED': 5, 'REGAINS': 5, 'CANDIDATES': 5, 'SHAREHOLDERS': 5, 'EHA': 5, 'PROCEDURE': 5, 'PERINATAL': 5, 'CARTILAGE': 5, 'PLATINUM': 5, 'LINES': 5, 'TIMELINE': 5, 'DOWNGRADED': 5, 'SUBJECTS': 5, 'TTP273': 5, 'VEDOTIN': 5, 'VMAT2': 5, 'ASN': 5, 'ADAPT': 5, 'CERC': 5, 'STATIN': 5, 'ADJUNCTIVE': 5, 'TYMPANOSTOMY': 5, 'CRS': 5, 'PREVIOUSLY': 5, 'FRANCE': 5, 'SECURE': 5, 'ARE': 5, 'TOWARD': 5, 'CAUSE': 5, '130277': 5, 'APAZIQUONE': 5, 'FUNCTIONAL': 5, 'DICERNA': 5, 'EORTC': 5, 'RESPIRATORY': 5, 'CYNAPSUS': 5, 'BEHCETS': 4, 'BRISTOL': 4, 'EVOFOSFAMIDE': 4, 'IPILIMUMAB': 4, 'HAND': 4, 'CORRELATIVE': 4, 'SNI': 4, 'INFLAMMATION': 4, '295': 4, 'NORMAL': 4, 'OPHTHALMOLOGY': 4, 'TRASTUZUMAB': 4, 'PEDIATRICS': 4, 'MANNKIND': 4, '106': 4, 'SELLS': 4, 'DROP': 4, 'INVOLVING': 4, 'DUET': 4, 'SUGGESTING': 4, 'SEAMLESS': 4, 'DESIRE': 4, 'PARAMETERS': 4, 'STANLEY': 4, 'ZENYAKU': 4, 'ANIMAL': 4, 'BB2121': 4, 'MORPHINE': 4, 'JOB': 4, 'EROSIVE': 4, 'EXTERNA': 4, 'UNSTOPPABLE': 4, 'BEGIN': 4, 'MEDIA': 4, 'POSSIBLE': 4, 'ACCORDING': 4, 'STUDYING': 4, 'SERVIER': 4, 'STRENGTHENS': 4, 'ONCE': 4, 'KYOWA': 4, 'RETIREMENT': 4, 'ANGIOGENIC': 4, 'PANOVA': 4, '6551T': 4, 'PERRY': 4, 'ACETATE': 4, 'KEEPING': 4, 'METHOD': 4, 'MILD': 4, 'RIGRODSKY': 4, 'NEONATAL': 4, 'NAIVE': 4, 'CHIEF': 4, 'KURLAND': 4, 'AMYLOIDOSIS': 4, 'COMPLICATED': 4, 'SPARING': 4, 'CLONALITY': 4, 'VOYAGER': 4, 'ATYPICAL': 4, 'CELLDEX': 4, 'EXCLUSIVITY': 4, 'PUBLIC': 4, 'TDT': 4, 'MATTHEW': 4, 'APPOINTMENT': 4, 'GLOMERULOSCLEROSIS': 4, 'DURABILITY': 4, 'BELOW': 4, 'VY': 4, 'FRANCHISE': 4, 'INTRATUMORAL': 4, 'DOSSIER': 4, 'CLASSIC': 4, 'OVERVIEW': 4, 'HI': 4, 'IMPEDES': 4, 'JMP': 4, 'GOG': 4, 'CONFIRM': 4, 'APPOINTS': 4, 'COURSE': 4, 'ALLOTMENT': 4, 'JOURNALS': 4, 'GERMANY': 4, 'CORD': 4, 'JAPANESE': 4, 'MERCK': 4, 'ANCHOR': 4, 'INITIATING': 4, 'PROTALIX': 4, 'REPAYMENT': 4, 'ALSO': 4, 'CANTOR': 4, 'SHOT': 4, 'SIGNIFICANTLY': 4, 'INFILTRATION': 4, 'INDUCES': 4, 'TUBES': 4, 'DIRECTION': 4, 'INSULIN': 4, 'DEPARTMENT': 4, 'HAEMOSTASIS': 4, 'CA4P': 4, 'MODIFIED': 4, 'ARROYO': 4, 'LUCINACTANT': 4, 'PONATINIB': 4, 'TRANSCATHETER': 4, 'PEPTIDE': 4, 'XMETA': 4, 'MD': 4, 'VALEANT': 4, 'VACCINES': 4, 'AGHD': 4, 'DESCRIBING': 4, 'ROBBINS': 4, 'CONJUNCTIVITIS': 4, 'MORGAN': 4, 'EXERCISES': 4, 'REACHING': 4, '37TH': 4, 'TARLOXOTINIB': 4, 'TUESDAY': 4, 'UREMIC': 4, 'RE': 4, 'SBIR': 4, 'PROPOSED': 4, 'PREVALENCE': 4, 'POTENT': 4, 'OPPORTUNITIES': 4, 'ITMN': 4, 'BAY41': 4, 'POPULATION': 4, 'AMENDED': 4, 'RECTAL': 4, 'TOLERABILITY': 4, 'TABLET': 4, 'PCDH19': 4, 'ANESTHESIOLOGY': 4, 'SPINAL': 4, 'EXACERBATION': 4, 'INCREASE': 4, 'EARNINGS': 4, 'CLL': 4, 'SURGING': 4, 'OBLIGATION': 4, 'PERINDOPRIL': 4, 'TGF': 4, 'VIOLATIONS': 4, '200': 4, 'METIV': 4, 'IMPORTANT': 4, 'POWDER': 4, 'ANTIBODIES': 4, 'ROOM': 4, 'CLINICALLY': 4, '60': 4, '65': 4, 'DROPS': 4, 'PRESENTING': 4, 'BURNS': 4, 'WAC': 4, 'WAS': 4, 'TRIGLYCERIDES': 4, 'DID': 4, 'HOURS': 4, 'LEADING': 4, 'CAPITAL': 4, 'IMPROVEMENTS': 4, 'ADJACENT': 4, '213': 4, 'VIAGENPUMATUCEL': 4, 'HBV': 4, 'TEXAS': 4, 'INJURY': 4, 'MODULATOR': 4, 'CONVERTIBLE': 4, 'IPO': 4, '28TH': 4, 'BRIGHT': 4, 'AURIS': 4, '75M': 4, 'OUTWEIGH': 4, 'FRAGMENT': 4, 'RIVAL': 4, 'LIPROTAMASE': 4, 'THROMBOCYTOPENIA': 4, 'STREAMS': 4, 'HOPE': 4, 'SEES': 4, 'RESISTANCE': 4, '3102': 4, 'GERMAN': 4, 'FLEXIBLE': 4, 'SIX': 4, 'ESPE': 4, 'REPERTOIRE': 4, 'ASTERIAS': 4, 'PLAINTIFF': 4, 'BIORESORBABLE': 4, 'ACCELERATION': 4, 'SELECTIVE': 4, 'TARGETS': 4, 'HCC': 4, 'ANALOG': 4, 'BRINEURA': 4, 'AADC01': 4, 'SEGMENTAL': 4, 'UNDERTREATED': 4, 'SPIN': 4, 'SK': 4, 'STEP': 4, 'ENHANCE': 4, 'UNVEILED': 4, 'MAKE': 4, 'POLYANGIITIS': 4, 'PERIODS': 4, 'EPIC': 4, 'CATARACT': 4, 'GRUNENTHAL': 4, 'LYMPHOCYTES': 4, 'ISTH': 4, 'SFY': 4, 'IPI': 4, 'REPORTING': 4, 'FALLS': 4, 'FORMULATION': 4, 'IT': 4, 'ET': 4, 'HYPOACTIVE': 4, 'DISCONTINUES': 4, 'THROUGH': 4, 'BB305': 4, 'DIMENSION': 4, 'SOARING': 4, 'SOCIETIES': 4, 'DISCLOSES': 4, 'IMMUNOGENIC': 4, 'SCHEDULE': 4, 'BEARING': 4, 'FISTULA': 4, 'HALFWAY': 4, 'CREATION': 4, 'NORTH': 4, 'EARLIER': 4, 'PATHOGENS': 4, 'SELECT': 4, 'TEAM': 4, 'TRANSFERS': 4, 'SPLIT': 4, 'MOVES': 4, 'INITIATIVES': 4, 'XA': 4, 'BEAT': 4, 'M': 4, 'KINASE': 4, 'OXI4503': 4, 'TTRSC02': 4, 'FORMERLY': 4, 'SYMPLMED': 4, 'RELIEF': 4, 'BACK': 4, 'EXOCRINE': 4, 'AWARD': 4, 'AST': 4, 'COMMITMENT': 4, 'TRANSLATIONAL': 4, 'REGAIN': 4, 'REVERSE': 4, 'REPLICATES': 4, 'DERMIRA': 4, 'TARGETING': 4, 'STROKE': 4, 'WARRANTS': 4, 'PREFERRED': 4, 'FACILITIES': 4, 'MICROBIOLOGY': 4, 'LEVI': 4, 'AVACOPAN': 4, 'PLUNGING': 4, 'TESTING': 4, 'DISCONTINUE': 4, 'ZOMBIE': 4, 'BEST': 4, 'PORTION': 4, 'PSMA': 4, 'VERY': 4, 'INCONTINENCE': 4, 'PHARMACOKINETICS': 4, 'MERRILL': 4, 'TRANSPLACENTAL': 4, 'RISKS': 4, 'NEED': 4, 'NOVARTIS': 4, 'DETERRENT': 4, 'IMMUNOSTIMULATORY': 4, 'MECHANICALLY': 4, 'QD': 4, 'BLOCKADE': 4, 'KIRIN': 4, 'NOTE': 4, 'COACT': 4, 'ESTROGEN': 4, 'P': 4, 'SARM': 4, 'FRIDAY': 4, 'TUMORAL': 4, 'MISLED': 4, '9MG': 4, 'OPDIVO': 4, 'REIMBURSEMENT': 4, 'UPBEAT': 4, 'ATTAINS': 4, 'MACIMORELIN': 4, 'NATURALLY': 4, 'SUPINOXINTM': 4, 'GREEN': 4, 'LYNCH': 4, 'PLAQUE': 4, 'SUBGROUP': 4, 'GVHD': 4, 'GUIDELINES': 4, 'BANK': 4, 'GENERATED': 4, 'DEFENSE': 4, 'FOLLOWS': 4, 'KILL': 4, 'MYERS': 4, '024': 4, 'LOCALIZES': 4, 'SYMPTOMS': 4, 'BUSINESS': 4, '89': 4, 'NECESSARY': 4, 'FLOP': 4, 'INSUFFICIENCY': 4, 'ULCERS': 4, 'SNDA': 4, 'ROCLATAN': 4, 'ANGIOSARCOMA': 4, 'ANGIOGENESIS': 4, 'INHALE': 4, 'OMP': 4, 'SELECTIVELY': 4, 'AAN': 4, 'BEHCET': 4, 'OPC1': 4, 'LICENSEE': 4, 'VARUBI': 4, 'DEBT': 4, 'PHACILITATE': 4, 'FILE': 4, 'PT': 4, 'PH': 4, 'ARTERIOVENOUS': 4, 'OBTAINING': 4, 'BEEN': 4, 'TRACT': 4, 'DSUVIA': 4, 'FITZGERALD': 4, 'DIFFUSE': 4, 'MERCURY': 4, 'FRED': 4, 'HERCULES': 4, 'CE': 4, 'VENTILATED': 4, 'ANALYZE': 4, 'ARQ': 4, 'ARM': 4, 'PAEDIATRIC': 4, 'THRESHOLD': 4, 'SPECIFIED': 4, 'THOSE': 4, 'INFILTRATING': 4, 'CNS': 4, 'SQUIBB': 4, 'SCIENCE': 4, '33RD': 4, 'THROMBOSIS': 4, 'ANDERSON': 4, 'THOMAS': 4, 'RECENTLY': 4, 'RECEIVE': 4, 'OFFICER': 4, 'TRANSITION': 4, 'HALTED': 4, 'MSD': 4, 'AGENUS': 4, 'EQUITY': 4, 'KORSINSKY': 4, 'LUCENTIS': 3, 'SPN': 3, 'EVALUATION': 3, 'DLBCL': 3, 'UROGENITAL': 3, 'ECCMID': 3, 'VS': 3, 'OTOLARYNGOLOGY': 3, 'ENT': 3, 'MEDICARE': 3, 'SUPPLY': 3, 'LOGGED': 3, 'SATIVEX': 3, 'PROFILE': 3, 'ICOSAPENT': 3, '1H17': 3, 'RESUBMITS': 3, '59R5': 3, 'CHEST': 3, 'VISITS': 3, 'NETTER': 3, 'DEMCIZUMAB': 3, 'PROCEEDING': 3, 'IMPROVE': 3, 'ACQUISITION': 3, 'CANCELLATION': 3, 'ANTISENSE': 3, 'OXYCODONE': 3, 'ASCP': 3, 'PATCH': 3, 'CONFIRMS': 3, 'SERIOUS': 3, 'OPTICA': 3, 'EXPERIMENTAL': 3, 'MEET': 3, 'EXPAND': 3, 'NCCN': 3, 'NAME': 3, 'CERTAIN': 3, 'IDWEEK': 3, 'ASP0113': 3, 'CYTOMEGALOVIRUS': 3, 'FUNDS': 3, 'MOVE': 3, 'SUBCUTANEOUSLY': 3, 'ABBVIE': 3, 'SUPERIORITY': 3, 'AUTHORITIES': 3, 'HE': 3, 'SUB': 3, 'HSP90': 3, 'FAVORABLE': 3, 'SUPERNUS': 3, 'INGREDIENT': 3, 'REDUCTIONS': 3, 'MARKETS': 3, 'ARTERIAL': 3, 'GLABELLAR': 3, '812': 3, 'AUTHORIZED': 3, 'LEADER': 3, 'INLYTA': 3, 'REMODELING': 3, 'HOLDS': 3, 'SOLITAIRE': 3, 'LATIN': 3, 'DATABASE': 3, 'ERA': 3, 'MEANINGFUL': 3, 'MACROLIDE': 3, 'PROGNOSIS': 3, 'WORLDWIDE': 3, 'COLITIS': 3, 'IMMUNOLOGICAL': 3, 'INTERSECT': 3, '1A': 3, 'ATS': 3, 'VICAL': 3, 'PARAGANGLIOMA': 3, 'RECOMMEND': 3, 'ANTIMICROBIAL': 3, 'EDTA': 3, 'SELICICLIB': 3, 'APPROVABLE': 3, 'VIBEX': 3, 'PUBLICATIONS': 3, 'METASTASES': 3, 'MUTATIONS': 3, 'NIAID': 3, 'CHS': 3, 'MATRX': 3, 'ISRAEL': 3, 'WETTER': 3, 'ULCERATIVE': 3, 'TRANSPLANT': 3, 'ORGAN': 3, 'ID': 3, 'LYMPHOBLASTIC': 3, 'GONORRHEA': 3, 'ADDED': 3, 'GENETICS': 3, 'ISSUED': 3, 'CHOLESTEROL': 3, 'CABP': 3, 'CLUSTERIN': 3, 'NO': 3, 'CRADA': 3, 'SUPPLIER': 3, 'MESOTHELIOMA': 3, 'STANDARD': 3, 'BESTFIT': 3, 'XENON': 3, 'FORUM': 3, 'CHICAGO': 3, 'AHA': 3, 'SCREENING': 3, 'GETTING': 3, 'PROTECTION': 3, 'BLA': 3, 'ANTIPLATELET': 3, 'CORRECTING': 3, 'IPSEN': 3, 'DTX101': 3, 'CAR': 3, 'CAD': 3, 'NEUROMYELITIS': 3, 'TRADEMARK': 3, 'MID': 3, 'ADDITION': 3, 'POSIDUR': 3, 'CORRELATE': 3, 'HDL': 3, 'RPX7009': 3, 'COMBINABILITY': 3, 'COLONIC': 3, 'PHASEOUT': 3, 'ANTARES': 3, 'HYPOTENSION': 3, 'EFFLUX': 3, 'RESUMES': 3, 'OUTCOME': 3, 'NEPHROLOGY': 3, '55TH': 3, 'RIBAXAMASE': 3, 'MIDDLE': 3, 'YORK': 3, 'SHOWED': 3, 'DOCETAXEL': 3, 'NDAS': 3, '7119': 3, 'KALYDECO': 3, 'NEEDED': 3, 'READY': 3, 'LABORATORIES': 3, 'PASSES': 3, 'REPLACING': 3, 'ATEASE': 3, 'MDV3100': 3, 'ALZHEIMER': 3, 'PODIUM': 3, 'ACT': 3, 'EAST': 3, 'ESSENTIAL': 3, 'ATTRACT': 3, 'WATER': 3, 'ONLY': 3, 'RESOLVE': 3, 'PHARMACOTHERAPY': 3, 'COHERUS': 3, 'PRODUCTS': 3, 'MILITARY': 3, 'ELDERLY': 3, 'MODULATING': 3, 'SATURN': 3, 'DRUGS': 3, 'BONE': 3, 'XEN801': 3, 'FORMS': 3, 'PARTICLES': 3, 'PROMOTER': 3, 'ABP': 3, 'CRMD003': 3, 'CENTRALIZED': 3, 'ABDOMINAL': 3, '700': 3, 'CANGRELOR': 3, 'POTENTIALLY': 3, 'EXCELLENCE': 3, 'APOLLO': 3, 'PROGRESSES': 3, 'ICAAC': 3, 'OTSUKA': 3, 'NEOADJUVANT': 3, 'SERUM': 3, 'TINNITUS': 3, 'NIH': 3, 'RATE': 3, 'CRE': 3, 'RESUBMITTED': 3, 'ALPINE': 3, '1420': 3, 'VIRAL': 3, 'MORE': 3, 'AMENDMENT': 3, 'BACTERIA': 3, 'DECENTRALIZED': 3, 'REDUCES': 3, 'SAMURAI': 3, 'CII': 3, 'INCREASED': 3, 'DEMAND': 2, 'HUMIRA': 2, '50TH': 2, 'INVITED': 2, 'MANUFACTURE': 2, 'SNO': 2, 'BRAND': 2, '21101': 2, 'IAP312': 2, 'COLO205': 2, 'OARSI': 2, 'ADDRESSING': 2, 'THERAVANCE': 2, 'MATCHED': 2, 'DETAILED': 2, 'CTA': 2, 'POLYCYTHEMIA': 2, 'PSYCHOPHARMACOLOGY': 2, 'DIFFERENT': 2, 'PYRIMIDINE': 2, 'ORTHOPEDIC': 2, 'EUROPHARMA': 2, 'ONE': 2, 'VIRUS': 2, 'ONT': 2, 'CATHETER': 2, 'CASKI': 2, 'CONDITIONS': 2, 'RECORDATI': 2, 'FUJI': 2, 'HAEMATOLOGY': 2, 'CEREBROVASCULAR': 2, 'MPNS': 2, '67TH': 2, 'MUTUAL': 2, 'BENEFICIAL': 2, 'ANTERIOR': 2, 'BIOSIMILAR': 2, 'CT': 2, 'BIOTIME': 2, 'TTR': 2, 'TERRAIN': 2, 'RESUME': 2, 'DISCUSSIONS': 2, '549': 2, 'CAPMATINIB': 2, 'TRIPTAN': 2, 'TNF': 2, 'CASCADIAN': 2, 'DMC': 2, 'REQUIRE': 2, '0298': 2, 'THAN': 2, '380': 2, 'HALF': 2, 'COHORTS': 2, 'HITS': 2, 'DOUBLING': 2, 'GERMLINE': 2, 'JAK': 2, 'SECURES': 2, 'ABILITY': 2, 'ZP': 2, 'XENOGRAFT': 2, 'OBJECTION': 2, 'BRITISH': 2, 'GALE': 2, '160': 2, 'PREVENTATIVE': 2, 'PRX': 2, 'SABCS': 2, 'SOMATIC': 2, 'EARNS': 2, 'MRCC': 2, 'TRUST': 2, 'SUBSTUDY': 2, 'COMPARATOR': 2, '52': 2, '4TH': 2, 'INNOVATE': 2, 'STREAMLINED': 2, 'BLINDING': 2, 'POOLED': 2, 'PBM': 2, 'VIFOR': 2, '56TH': 2, 'RENEWAL': 2, 'CAUSED': 2, 'CRAMER': 2, 'PICKS': 2, 'SLE': 2, 'DIFFERENTIATED': 2, 'PREVENTS': 2, 'REINFORCE': 2, 'OPTIMIZATION': 2, 'ASSIGNMENT': 2, 'GREATER': 2, 'COGNITIVE': 2, 'NOTCH2': 2, 'WIRE': 2, 'EAR': 2, '087': 2, 'SRSE': 2, 'RESECTABLE': 2, 'FX006': 2, 'MF': 2, 'RHIGM22': 2, '7TH': 2, 'ORIENT': 2, 'EMERGING': 2, 'RETINA': 2, 'SPECIALISED': 2, 'EULAR': 2, 'KOL': 2, 'AHEAD': 2, 'WORLDSYMPOSIUM': 2, 'CAPECITABINE': 2, '145': 2, 'CELLULAR': 2, 'PASS': 2, '38543': 2, 'SAP303': 2, 'EDEMA': 2, 'RA': 2, 'ALCOHOL': 2, 'REQUIRED': 2, '70TH': 2, 'MEDIVATION': 2, 'DYNAMO': 2, 'LIMB': 2, '1Q': 2, 'REFUSAL': 2, 'VALBENAZINE': 2, 'EXISTING': 2, 'DL': 2, 'H69': 2, 'CALIFORNIA': 2, 'PROVIDING': 2, 'APPROVED': 2, 'MICROSCOPIC': 2, 'REQUIRING': 2, 'SMOKING': 2, 'FIXED': 2, 'TURKEY': 2, 'SCHEDULES': 2, 'HYPERPHOSPHATEMIA': 2, 'AVAILABILITY': 2, 'PV': 2, 'HSV': 2, 'C5AR': 2, 'HAD': 2, 'AWARENESS': 2, 'SYK': 2, 'DECREASES': 2, 'INFORMS': 2, 'ANTICOAGULANT': 2, 'CIRM': 2, 'SOUTHEAST': 2, 'IDENTIFIES': 2, 'CTG': 2, 'FACIOSCAPULOHUMERAL': 2, '48TH': 2, 'OWNED': 2, 'TOURETTE': 2, 'AERI': 2, 'INNER': 2, 'ACRX': 2, 'CHEMOREFRACTORY': 2, 'CATECHOLAMINE': 2, 'EPA': 2, 'FROWN': 2, 'ECTRIMS': 2, 'DESIGNED': 2, 'SVR': 2, 'CILOLEUCEL': 2, 'CYCLE': 2, '72': 2, 'CASE': 2, 'BOYS': 2, 'AMPYRA': 2, 'TRANSTHYRETIN': 2, 'ORIGIN': 2, 'ELI': 2, '103RD': 2, 'SCORES': 2, 'AXICABTAGENE': 2, 'ZOSANO': 2, 'NMIBC': 2, 'MEASUREMENTS': 2, 'INTENSITY': 2, 'SWISSMEDIC': 2, 'GENETIC': 2, 'HISTORY': 2, '12TH': 2, 'RIBBON': 2, 'JIM': 2, 'CONSUMER': 2, 'DUCTAL': 2, 'CAMPAIGN': 2, 'NOTCH': 2, 'VENOUS': 2, 'CARBAPENEM': 2, 'HYPERICIN': 2, 'HCL': 2, 'TENOFOVIR': 2, 'OPINIONS': 2, 'RECOGNIZED': 2, 'KNOWN': 2, 'OUT': 2, 'ACHIEVE': 2, 'ADVANTAGE': 2, 'REVEFENACIN': 2, 'DAILY': 2, 'OBSTRUCTIVE': 2, 'INDOLENT': 2, 'TRENDS': 2, 'DEMONSTRATED': 2, 'STANDARDIZATION': 2, 'BROAD': 2, 'GIRDLE': 2, 'DAMAGE': 2, 'PURINE': 2, 'DIALYSIS': 2, 'LEBANON': 2, 'SCAVENGER': 2, 'EF': 2, 'ATOPIC': 2, 'BELMONT': 2, 'INADEQUATE': 2, 'CODE': 2, 'LIPOQUIN': 2, 'LIQUID': 2, 'NEUTROLINA': 2, 'MYLAN': 2, 'ACHIEVEMENT': 2, 'VERA': 2, 'BIOAVAILABLE': 2, 'LINZESS': 2, 'QUALIFIED': 2, 'DOSIMETRY': 2, 'MYELOPROLIFERATIVE': 2, '1467': 2, 'WASHINGTON': 2, 'GRIFOLS': 2, 'AGITATION': 2, 'HRAS': 2, 'PROTECTING': 2, 'INCLUSION': 2, 'NOTIFICATION': 2, 'DIFFICULTIES': 2, 'FORMULARIES': 2, 'TRIPLET': 2, '9TH': 2, 'ANY': 2, 'SHEDDING': 2, '53RD': 2, 'SENSITIVE': 2, 'ENDOMETRIAL': 2, 'CONDUCTS': 2, 'ARMS': 2, 'INVESTMENT': 2, 'STEROID': 2, 'HEP': 2, 'OBSERVED': 2, 'BEAM': 2, 'FINDING': 2, '5AR': 2, '007': 2, '006': 2, 'THROMBOEMBOLISM': 2, 'STRIVE': 2, 'SVR12': 2, 'PURE': 2, 'AHUS': 2, 'DART': 2, 'DEFICITS': 2, '8220': 2, '8221': 2, 'IMPLANTS': 2, '4208': 2, 'BLOCK': 2, '300': 2, 'DERMATITIS': 2, 'ACC': 2, 'SPECT': 2, '7106': 2, 'GRANULOMATOSIS': 2, 'ND0612L': 2, 'EVIDENCE': 2, 'TD': 2, 'TIMING': 2, 'NEOPLASMS': 2, 'SUMMARIZES': 2, 'ENHANCED': 2, 'SITU': 2, 'ENTEROBACTERIACEAE': 2, 'VITAE': 2, 'MIGRATION': 2, 'PHOTO': 2, 'JANUS': 2, 'NOMINATION': 2, 'SPONSOR': 2, 'AMBULATORY': 2, 'COMMENCE': 2, 'KOGYO': 2, 'ESTATE': 2, 'CESSATION': 2, 'ANESTHESIA': 2, 'VIIA': 2, 'BCG': 2, 'PRIORITIES': 2, 'OPRX': 2, 'TANKS': 2, 'REMAINS': 2, 'SCORE': 2, 'CONDUCTED': 2, 'REGORAFENIB': 2, 'SURVEILLANCE': 2, '130': 2, 'TREMOR': 2, 'WHOLLY': 2, 'BURDEN': 2, 'CSO': 2, 'LHRH': 2, 'QUARTERLY': 2, 'PROJECT': 2, 'AMMONIA': 2, 'TERMINATION': 2, 'EFFECTIVENESS': 2, 'BLUE': 2, 'ITI': 2, 'VIVO': 2, 'RECONFIRMS': 2, 'NUCLEAR': 2, 'VERASTEM': 2, 'EXTERNALLY': 2, 'VESIGENURTACEL': 2, 'THEIR': 2, 'ASPIRIN': 2, 'INVESTIGATOR': 2, 'PORCINE': 2, 'EXPECTS': 2, 'SELL': 2, 'ENZYME': 2, 'BIRMINGHAM': 2, 'CRP': 2, 'FORMULATIONS': 2, 'DIRECT': 2, 'LIABILITY': 2, 'LANDSCAPE': 2, 'UNIT': 2, 'RELEASING': 2, 'ACCELERATES': 2, 'CIRRHOSIS': 2, 'OLE': 2, 'CHORIOCARCINOMA': 2, 'FORMULARY': 2, 'FRONT': 2, 'DUODOPA': 2, 'RANGING': 2, 'NECK': 2, 'RAFA': 2, 'PERSISTENT': 2, 'ACNE': 2, 'TAIWAN': 2, 'SELECTS': 2, 'COMPARISON': 2, 'ARB': 2, 'DEFICIENT': 2, 'CARDIAC': 2, 'CONFIRMATORY': 2, 'INFLAMMATORY': 2, 'RELAUNCHES': 2, 'UK': 2, 'VTP': 2, 'ARBUTUS': 2, 'AEZS': 2, 'FAILURE': 2, 'SIMPLICITY': 2, 'FSHD': 2, 'INCREASES': 2, 'ELECTS': 2, 'SOTATERCEPT': 2, 'GILEAD': 2, 'MODIFICATIONS': 1, '2031': 1, 'READTHROUGH': 1, 'MUTATED': 1, 'EISAI': 1, 'AMONG': 1, 'BASELINE': 1, 'VOLUNTEERS': 1, 'ASCPT': 1, 'SAKURA': 1, 'GM': 1, 'LIGAND': 1, 'ASSETS': 1, 'PRIX': 1, 'ABSORPTION': 1, 'NEAR': 1, 'UNFAVORABLE': 1, 'VASOCONSTRICTIVE': 1, 'INTRAVENOUSLY': 1, 'INTELLECTUAL': 1, 'BATCHES': 1, 'DYSLIPIDEMIA': 1, 'HALTS': 1, 'WEBINAR': 1, 'CARDIOPULMONARY': 1, 'MEXICO': 1, 'CDI': 1, 'PREPAREDNESS': 1, 'PROMOTION': 1, 'SOMAKIT': 1, 'REFUSE': 1, 'METHODS': 1, 'PACIFIC': 1, 'GOODS': 1, 'PUBLISH': 1, '99': 1, 'DILUTIVE': 1, 'IMMUNOLOGISTS': 1, 'BOTTLE': 1, 'IMMUNOGEN': 1, 'ELECTION': 1, 'BODY': 1, 'RATING': 1, 'INTELLIGENCE': 1, 'HERON': 1, 'APA': 1, 'REGIMENS': 1, 'SAUDI': 1, 'VAPENDAVIR': 1, 'ICE': 1, 'CTS': 1, 'CD40': 1, 'CAPTISOL': 1, 'PLASMA': 1, 'IDO': 1, 'INTENDED': 1, 'CLOSES': 1, 'TECENTRIQ': 1, '3RD': 1, 'PRO': 1, 'QAPZOLA': 1, 'RESPONDER': 1, 'MAJORELLE': 1, 'BLUMBERG': 1, 'GAMMA': 1, 'SMOKERS': 1, 'AMRN': 1, 'INSTILLATION': 1, 'TOXICITY': 1, 'TRANSFORM': 1, 'INTRANASAL': 1, 'NAUSEA': 1, 'CZECH': 1, 'ANTIBIOTICS': 1, 'INVESTIGATED': 1, 'ROCHE': 1, 'DETAILS': 1, 'SIGNALS': 1, 'FORECAST': 1, 'TIME': 1, 'NEXMED': 1, 'VACCINATED': 1, 'USED': 1, 'HIGHLIGHT': 1, '009': 1, 'ADDS': 1, 'PIG': 1, 'LIPOPROTEIN': 1, 'ATLANTA': 1, '1504': 1, 'CUBI': 1, 'NEWLY': 1, '092': 1, 'Q3': 1, 'AFRICAN': 1, 'DIAGNOSED': 1, 'NEUROBIOLOGY': 1, 'APPROVALS': 1, 'MALES': 1, 'HOMOZYGOUS': 1, 'BARUCH': 1, 'HYPERCHOLESTEROLEMIA': 1, 'QS': 1, 'HEPATORENAL': 1, 'MAYO': 1, 'ORACLE': 1, 'DIEGO': 1, 'AAPM': 1, 'VALIDATE': 1, 'PDE': 1, 'PAN': 1, 'OPT': 1, 'PROTEIN': 1, 'LOCALLY': 1, 'AXITINIB': 1, 'PLUNGES': 1, 'SELLING': 1, 'EXTENDS': 1, 'AVIRAGEN': 1, 'THERAPEUTICALLY': 1, 'PARTICLE': 1, 'NAB': 1, 'NEUROIMAGING': 1, 'STANDARDIZED': 1, 'PROGRESSING': 1, 'MYCOBACTERIAL': 1, 'SEEKS': 1, 'BUY': 1, 'STARTED': 1, 'CONNECTIVE': 1, 'COOPERATIVE': 1, 'GENUINE': 1, 'EXPEDITED': 1, 'DEADLY': 1, 'UNTIL': 1, 'NASAL': 1, '5873': 1, 'DANA': 1, 'BRCANESS': 1, 'PROTECTS': 1, 'SPIRITUS': 1, 'ASSAY': 1, '250': 1, '255': 1, 'WITHDRAWS': 1, 'FEMALES': 1, 'GENENTECH': 1, 'READINESS': 1, 'IRON': 1, '4Q': 1, '120TH': 1, 'QUICKSHOT': 1, 'TDM': 1, '32ND': 1, 'ANNALS': 1, 'NMO': 1, 'APPEAL': 1, 'ENGINEERED': 1, 'RELATING': 1, 'TAKES': 1, 'NHE3': 1, 'ANOTHER': 1, 'XERMELO': 1, 'EMERGE': 1, 'VE': 1, 'REQUEST': 1, 'CHIMERIX': 1, 'INTRODUCED': 1, 'MISSED': 1, 'RECOGNITION': 1, 'IRRITATION': 1, 'PLACEMENT': 1, 'FIFTY': 1, 'SPECIALTY': 1, 'CIMT': 1, 'WOUND': 1, 'MARC': 1, 'BECKER': 1, 'ESTABLISH': 1, 'PREVENTIVE': 1, 'HERCEPTIN': 1, 'SINUSITIS': 1, 'NACFC': 1, 'HA': 1, 'HD': 1, 'HENGRUI': 1, 'SCALING': 1, 'PRODUCTION': 1, 'CONNECT': 1, 'HDAC': 1, 'REPEAT': 1, 'TRAINING': 1, 'SIZE': 1, 'CETUXIMAB': 1, 'STANDARDS': 1, 'RATER': 1, 'ISIS': 1, 'OPTIC': 1, 'MYOLOGY': 1, 'DNA': 1, 'TITRATION': 1, 'SUCCESSES': 1, '228': 1, 'BXMT': 1, 'DETERRENCE': 1, 'WILLIAM': 1, 'IMMUNOTHERAPEUTIC': 1, 'LOWERING': 1, 'GROUNDBREAKING': 1, 'LIKE': 1, 'EXECUTIVES': 1, 'HOC': 1, 'SUGGEST': 1, 'VALUE': 1, 'NEARLY': 1, 'GALIEN': 1, 'FRANCISCO': 1, 'PREPARING': 1, 'COMPANION': 1, 'CONCLUDES': 1, 'HUMANIZED': 1, 'CROSSTALK': 1, 'MEDGENICS': 1, 'TREATMENTS': 1, 'MYOPATHIES': 1, 'AFFECTED': 1, 'MABVAX': 1, 'GMBH': 1, 'ADVERTISING': 1, 'CML': 1, 'RUBRACA': 1, 'ADVICE': 1, 'HEXAL': 1, 'VOMITING': 1, 'CMV': 1, 'BIOLOGICAL': 1, 'FOLD': 1, 'SMALLER': 1, 'MODIFIES': 1, 'FREQUENT': 1, 'AFRICA': 1, 'HEAVY': 1, 'MAGE': 1, 'ORIGINATING': 1, 'NEOPHARM': 1, 'ENROLS': 1, 'BLOG': 1, 'INO': 1, 'TRANSFORMED': 1, 'UTILITY': 1, 'DEMONSTRATION': 1, 'SIDES': 1, 'SYMPOSIA': 1, 'ANDROGENS': 1, 'CYDEX': 1, 'EXECUTIVE': 1, 'SPRAY': 1, 'SETS': 1, 'VEGF': 1, 'AUA': 1, 'CONSTELLA': 1, 'HALLUCINATIONS': 1, 'INSPIRE': 1, 'PROCEEDINGS': 1, 'MMM': 1, 'BIOELECTRONIC': 1, 'UPPED': 1, 'CARCINOMAS': 1, 'ACADEMIC': 1, 'CELG': 1, 'WLFC': 1, 'DELUSIONS': 1, 'ANTIEPILEPTIC': 1, 'JBMR': 1, 'TFL': 1, 'CALCIFICATION': 1, '122': 1, 'RETINAL': 1, 'ATAXIA': 1, 'SANDOZ': 1, 'STELLAR': 1, 'PHOSPHORUS': 1, 'INSYS': 1, 'BASF': 1, 'ATORVASTATIN': 1, 'INATTENTIVE': 1, 'CHEMOTHERAPIES': 1, 'FRACTURE': 1, 'TTP399': 1, 'EMERGENCE': 1, 'AXOVANT': 1, 'ALMIRALL': 1, '5TH': 1, 'EIGHT': 1, 'ADVANCING': 1, 'ABBOTT': 1, 'INTENTION': 1, 'TERMINATE': 1, 'CENTERS': 1, 'MYELOMONOCYTIC': 1, 'RECONNECTSTUDY': 1, 'PREMENOPAUSAL': 1, 'HIGHER': 1, 'UROLOGY': 1, 'MANIPULATION': 1, 'SURVIVORSHIP': 1, 'MENTAL': 1, 'REVISED': 1, 'AMPLIFIED': 1, 'WORRY': 1, 'RIGHT': 1, 'NEURO': 1, 'BASIS': 1, 'DE': 1, 'DC': 1, 'GREECE': 1, 'EVERCORE': 1, 'CITY': 1, 'PSORIATIC': 1, 'EXTEND': 1, 'IASLC': 1, 'SUNITINIB': 1, 'OUTPERFORMS': 1, 'ACTIVITIES': 1, 'ARIEL2': 1, 'XIV': 1, 'ADAPTIVE': 1, 'BEHAVIORS': 1, '14TH': 1, 'AFFIRM': 1, 'ROOF': 1, 'LDL': 1, 'IRELAND': 1, 'MITOTIC': 1, 'PERSONALIZED': 1, 'PROVIDERS': 1, 'PHARMASOURCE': 1, 'ONESTEP': 1, 'MONOCLONAL': 1, 'EXPERIENCE': 1, 'INSTITUTES': 1, 'COM': 1, 'ROLES': 1, 'CR2': 1, 'MAXIMIZE': 1, 'SOARS': 1, 'COMMUNICATIONS': 1, '30TH': 1, 'BIOAVAILABILITY': 1, 'MKM': 1, 'SWOG': 1, 'DIAGNOSTIC': 1, '39TH': 1, 'OUTLINING': 1, 'HIGHLIGHTING': 1, 'INFORMED': 1, 'SURROUNDING': 1, 'SUBSTANTIAL': 1, 'REPUBLIC': 1, 'PROPIETARY': 1, 'TELESTAR': 1, 'IF': 1, 'COLLABORATE': 1, 'RATIFIES': 1, 'LUNAR': 1, '77': 1, 'THOUGH': 1, 'UNOPROSTONE': 1, 'SUBTYPES': 1, 'EIGHTH': 1, 'SHOCK': 1, 'ORGANIZATION': 1, 'ANGELMAN': 1, 'ANTIVIRAL': 1, 'MEDIASTINAL': 1, 'ISOPROPYL': 1, 'DENMARK': 1, 'COMES': 1, 'TREATS': 1, 'EAU': 1, 'CHAIRMAN': 1, 'QUITE': 1, 'GENETICALLY': 1, 'PK': 1, 'SIGMA': 1, 'NIRAPARIB': 1, 'MAKES': 1, 'API': 1, 'KEYSTONE': 1, 'CURATIVE': 1, 'TRC': 1, 'VOTED': 1, 'MOLECULAR': 1, 'SAVE': 1, 'ENGAGEMENT': 1, 'NEOBOMB1': 1, 'ALLIANCE': 1, 'ROUTE': 1, 'RESISTS': 1, 'INDIGO': 1, 'NA': 1, '751': 1, 'J': 1, 'LOSES': 1, 'PROMOTE': 1, 'FRME': 1, 'TARDIVE': 1, 'BROADER': 1, 'EPACADOSTAT': 1, 'STIMULANT': 1, 'SEVERAL': 1, 'INSTITUTIONAL': 1, 'SGO': 1, 'ICC': 1, 'IVREA': 1, 'TANABE': 1, 'VANCOUVER': 1, '486': 1, 'RECEIVED': 1, 'ASTHMA': 1, 'BARCLAYS': 1, 'BRAF': 1, 'ROLLING': 1, 'POPS': 1, 'TAT': 1, 'TAU': 1, 'TUBERCULOUS': 1, 'FORCE': 1, 'ANTICIPATED': 1, 'TAF': 1, 'ARIPIPRAZOLE': 1, 'SITES': 1, 'AMZN': 1, 'BIOLOGY': 1, 'PACE': 1, 'LEICA': 1, 'INSTITUTIONS': 1, 'STOCKHOLM': 1, 'STRATUM': 1, 'LOAD': 1, 'PLANTAR': 1, 'ONCOGENE': 1, 'DELETERIOUS': 1, 'VEHICLE': 1, 'NASPGHAN': 1, 'PRGO': 1, 'LEVITON': 1, 'GLORIA': 1, 'CLEARED': 1, 'PINNACLE': 1, 'SENSITIZATION': 1, 'AAHKS': 1, 'KAPPA': 1, 'FEDERAL': 1, 'STIFFNESS': 1, 'ENROLL': 1, 'PRORKAMBI': 1, 'PAMREVLUMAB': 1, 'CONFIRMATION': 1, 'NFC': 1, 'FOLLICULAR': 1, 'RESPONSIBILITY': 1, 'KICKS': 1, 'HEPATOLOGY': 1, 'INTERACTION': 1, 'PPG': 1, 'DISTINCT': 1, 'PRODUCE': 1, 'SPOTLIGHTING': 1, 'EXALIDEX': 1, 'INSIGHT': 1, 'CONTINUOUS': 1, 'MANUFACTURER': 1, 'HAFC': 1, 'DESCRIBES': 1, 'ANTIPSYCHOTIC': 1, 'NEUROLOGICAL': 1, 'VENETOCLAX': 1, 'ARVO': 1, 'BUNIONECTOMY': 1, 'CRV431': 1, 'ED': 1, 'EC': 1, 'WILD': 1, 'PAPER': 1, 'UCSF': 1, 'INSURANCE': 1, 'LEWY': 1, 'COURT': 1, 'METABOLISM': 1, 'CONSORTIUM': 1, 'REASONS': 1, 'XIII': 1, 'BIENNIAL': 1, 'VACCINATION': 1, 'SINCE': 1, 'CLINIC': 1, 'DLL4': 1, 'DIFFERENCE': 1, 'EFFICACIOUS': 1, 'CAROTUXIMAB': 1, 'EXAMINE': 1, 'INDIVIDUALIZED': 1, 'ANTAGONIST': 1, 'WORKSHOP': 1, 'RANDOMIZES': 1, '700TH': 1, 'MANTLE': 1, 'ENGAGES': 1, 'TACTT3': 1, 'PALADIN': 1, 'SANTEN': 1, 'ATHOS': 1, 'VASCULAR': 1, 'C1100': 1, 'INAUGURAL': 1, 'SYNERGISTICALLY': 1, '4230': 1, 'FINANCING': 1, 'COST': 1, 'CRMD': 1, 'SUBMITTED': 1, 'INTRAVESICAL': 1, 'PSEUDOMONAS': 1, 'SCISTAR': 1, 'CHEMPORT': 1, 'EZETIMIBE': 1, 'CONNECTION': 1, 'MONACO': 1, 'MUSCULOSKELETAL': 1, 'SUMMER': 1, 'FARBER': 1, 'CARBIDOPA': 1, 'METABOLIC': 1, 'CHARACTERISTICS': 1, 'DOYLE': 1, 'NEGOTIATIONS': 1, 'SHIPMENT': 1, 'NEEDS': 1, 'NDD': 1, 'INITIATIVE': 1, 'DOUBLES': 1, 'UNRESPONSIVE': 1, 'UROTHELIAL': 1, 'COMPARABLE': 1, '35': 1, 'PANCREAS': 1, 'OBLIGATIONS': 1, 'ECFS': 1, '899': 1, 'MONTHS': 1, 'KOWA': 1, 'AUSTRALIAN': 1, 'LUXEMBOURG': 1, 'GVAX': 1, 'OPENING': 1, 'ACTIMMUNE': 1, 'HAKKO': 1, 'SWEDEN': 1, 'UCB': 1, 'PREDOMINANTLY': 1, 'MOVER': 1, 'USAN': 1, 'CERTIFICATION': 1, 'COMPASSIONATE': 1, 'ALLOWING': 1, 'SURPASSES': 1, 'JIANGSU': 1, 'AERUGINOSA': 1, 'AMD': 1, 'PARENT': 1, 'GUIDE': 1, 'DELIVERY': 1, 'DEVELOPED': 1, 'DEVELOPER': 1, 'TWELVE': 1, 'TRC102': 1, 'LEAKER': 1, 'ENABLES': 1, 'FLAGGED': 1, 'SLUMP': 1, 'FAILS': 1, 'IONTOPHORETIC': 1, 'MDR': 1, 'ORKAMBITM': 1, 'ACCRUAL': 1, 'DIAZEPAM': 1, 'REMISSION': 1, 'REIS': 1, 'BOND': 1, 'RUSSIA': 1, 'PNETS': 1, 'A3': 1, 'INVESTIGATORS': 1, 'AF': 1, 'FINLAND': 1, 'ARLZ': 1, 'RATIONALE': 1, 'ACKNOWLEDGMENT': 1, 'GENERIC': 1, 'PSYCHIATRY': 1, '019': 1, 'IMPROVES': 1, 'EYLEA': 1, 'ECONOMIC': 1, 'KADCYLA': 1, 'AUTHORIZATIONS': 1, 'TACTT2': 1, 'CONCOMITANT': 1, 'LAD': 1, 'INDUSTRY': 1, 'NETHERLANDS': 1, 'INUV': 1, 'UPON': 1, 'INNATE': 1, 'SEPTIC': 1, 'FULLY': 1, '24TH': 1, 'DEVELOPMENTS': 1, '38': 1, 'TABLETS': 1, 'ACTAVIS': 1, 'RECIPIENTS': 1, 'SMT': 1, 'FASCIITIS': 1, 'HORIZON': 1, 'RECOVERED': 1, 'ANNOUNCING': 1, 'ERS': 1, 'MVT': 1, 'ABOVE': 1, 'LARGEST': 1, 'MITSUBISHI': 1, 'SPOTLIGHTS': 1, 'PURSUE': 1, 'OPERATIONS': 1, '417': 1, 'TREND': 1, 'ABL': 1, 'ARABIA': 1, 'STOCKS': 1, 'EPILEPSIES': 1, 'HTX': 1, 'APOLIPOPROTEIN': 1, 'TOGETHER': 1, 'ASSERTS': 1, 'MELLITUS': 1, 'NHS': 1, 'STRENGTHEN': 1, 'BOLSTERS': 1, 'HYPOMETHYLATING': 1, 'REACH': 1, 'COMMENTS': 1, '82': 1, 'EFFORTS': 1, 'TOXINS': 1, 'JOINT': 1, 'JAMA': 1, '21M18': 1, 'TUBE': 1, 'FIBROTIC': 1, 'HOSPITALIZED': 1, 'SPRING': 1, 'PRECLINCAL': 1, 'CURE': 1, 'NF': 1, 'SHOWCASES': 1, 'GROUP': 1, 'ESTABLISHMENT': 1, 'FEASIBILITY': 1, 'SHOWCASE': 1, 'PSYCHIATRIC': 1, 'EOQUIN': 1, 'DUO': 1, 'GAIT': 1, 'CONFIDENCE': 1, 'HERE': 1, 'UNH': 1, 'RESEARCHERS': 1, 'KB': 1, 'FLEXTRONICS': 1, 'CLOSTRIDIUM': 1, 'CAPSULE': 1, 'ATHEROGENIC': 1, 'AAV': 1, 'BID': 1, 'COLLABORATES': 1, 'BIT': 1, 'COMPOUNDS': 1, 'UPGRADES': 1, 'OVEREXPRESSING': 1, 'MCL': 1, 'RESPONSES': 1, 'ELICITS': 1, 'HARBIN': 1, 'ACHIEVED': 1, 'COMPRISING': 1, 'TRANSACTION': 1, 'ABRAMSON': 1, 'ORGANISMS': 1, 'MINUTES': 1, 'SINUS': 1, 'ACTIVEXTEND': 1, 'NATURAL': 1, 'FACILITY': 1, 'LAUROXIL': 1, 'NELOTANSERIN': 1, 'ALBUMINURIA': 1, 'GEORGE': 1, 'TAPPAS': 1, 'SECURING': 1, 'PENNSYLVANIA': 1, 'VOTRIENT': 1, 'MODIFY': 1, 'AUTHORISATION': 1, 'ERIBULIN': 1, 'CRI': 1, 'PMBCL': 1, 'MEASURING': 1, 'ASGCT': 1, 'ELIS': 1, 'SLOVAKIA': 1, 'NAMED': 1, 'COMBINATIONS': 1, 'CATEGORY': 1, 'INCLUSIVE': 1, 'CR1': 1, 'PIVAC': 1, 'MORBID': 1, 'ACCELERATE': 1, 'PNTM': 1, 'ARGENTINA': 1, 'DENIES': 1, 'MARK2': 1, '74TH': 1, 'DCIS': 1, 'IMGN': 1, 'ANTIEMESIS': 1, 'MORTALITY': 1, 'EPISODIC': 1, 'PROPERTY': 1, 'STRATEGIES': 1, 'LEVO': 1, 'INOPERABLE': 1, 'ILLNESS': 1, 'FAILING': 1, 'ENCORAFENIB': 1, 'JCI': 1, 'BACTERICIDAL': 1, 'PENETRATION': 1, 'INTERFERON': 1, 'MARKING': 1, 'PPMD': 1, 'T1D': 1, 'ASSESSING': 1, 'STRATA': 1, 'PLANNING': 1, 'RECEIVING': 1, 'ADDITIVE': 1, 'NOVASEP': 1, 'LENGTH': 1, 'CHARM': 1, 'CONCENTRATION': 1, 'INTERRUPTION': 1, 'OPTIMIZING': 1, 'DEMENTIA': 1, 'DIOSYNTH': 1, 'KING': 1, 'ANRS': 1, 'BCR': 1, 'MEASURE': 1, 'UNRESECTABLE': 1, 'EYE': 1, 'USAGE': 1, 'OBESITY': 1, 'LOCALIZED': 1, 'GMCR': 1, 'BUPRENORPHINE': 1, 'EDUCATION': 1, '68TH': 1, 'TRV130': 1, 'EATI': 1, 'MIXED': 1, 'IDA': 1, 'APPROVE': 1, 'BINIMETINIB': 1, 'NASDAQ': 1, 'ACTRIMS': 1, 'BENZODIAZEPINE': 1, 'QUALIFYING': 1, 'BELGIUM': 1, 'LABORATOIRES': 1, 'FRIEDREICH': 1, 'ELSEVIER': 1, 'MARINE': 1, 'RETROSPECTIVE': 1, 'FOREST': 1, 'FOLFIRINOX': 1, 'BIOTECHNOLOGIES': 1, 'CF': 1, 'VOTE': 1})